nach oben

Erschienen in:

10.05.2018 | Original Paper

Gadolinium-based contrast agents induce gadolinium deposits in cerebral vessel walls, while the neuropil is not affected: an autopsy study

verfasst von: Stefanie Fingerhut, Michael Sperling, Markus Holling, Thomas Niederstadt, Thomas Allkemper, Alexander Radbruch, Walter Heindel, Werner Paulus, Astrid Jeibmann, Uwe Karst

Erschienen in: Acta Neuropathologica | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Recent studies showed gadolinium depositions following serial administrations of gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging examinations in various parts of the brain with the dentate nucleus (DN) being most affected. Even though no clinical correlates of the deposits are known yet, an intensive debate developed if this might be harmful. The aim of the current study was to specify the gadolinium distribution in brain tissue of patients who received serial injections of GBCAs in the low-µm range and to explore any potential pathological tissue changes caused by gadolinium deposits. Thirteen autopsy cases—eight receiving GBCA administrations, five serving as controls—were identified and analyzed. For all patients, total gadolinium quantification after acidic digestion by means of inductively coupled plasma-mass spectrometry (ICP-MS) was performed. Six cases were utilized for the spatially resolved quantification of gadolinium within the cerebellum and the basal ganglia by means of high-resolution laser ablation (LA)-ICP-MS. Histopathological and immunohistochemical examinations were performed to determine tissue reactions. LA-ICP-MS revealed gadolinium depositions in the walls of small blood vessels of the DN in all GBCA exposed patients, while no gadolinium was found in the control group. Additionally, the detection of phosphorus and metals like copper, zinc and iron provides evidence that transmetalation reactions might have occurred. No significant pathological changes of the brain tissue in the vicinity of the DN with respect to micro-/astrogliosis and neuronal loss were found in any of the patients. This notably holds true even for a patient who died from nephrogenic systemic fibrosis exhibiting extremely high gadolinium concentrations within the DN. The findings show that gadolinium depositions in the brain are restricted to blood vessel walls, while the neuropil is spared and apparent cellular reactions are absent.

Nur mit Berechtigung zugänglich

Aime S, Caravan P (2009) Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging 30:1259–1267. https://doi.org/10.1002/jmri.21969 CrossRefPubMedPubMedCentral

Birka M, Wentker KS, Lusmöller E, Arheilger B, Wehe CA, Sperling M, Stadler R, Karst U (2015) Diagnosis of nephrogenic systemic fibrosis by means of elemental bioimaging and speciation analysis. Anal Chem 87:3321–3328. https://doi.org/10.1021/ac504488k CrossRefPubMed

Cao Y, Huang DQ, Shih G, Prince MR (2016) Signal change in the dentate nucleus on T1-weighted MR images after multiple administrations of gadopentetate dimeglumine versus gadobutrol. Am J Roentgenol 206:414–419. https://doi.org/10.2214/Ajr.15.15327 CrossRef

Cao Y, Zhang Y, Shih G, Zhang Y, Bohmart A, Hecht EM, Prince MR (2016) Effect of renal function on gadolinium-related signal increases on unenhanced T1-weighted brain magnetic resonance imaging. Investig Radiol 51:677–682. https://doi.org/10.1097/Rli.0000000000000294 CrossRef

Fingerhut S, Niehoff AC, Sperling M, Jeibmann A, Paulus W, Niederstadt T, Allkemper T, Heindel W, Holling M, Karst U (2018) Spatially resolved quantification of gadolinium deposited in the brain of a patient treated with gadolinium-based contrast agents. J Trace Elem Med Biol 45:125–130. https://doi.org/10.1016/j.jtemb.2017.10.004 CrossRefPubMed

Frenzel T, Apte C, Jost G, Schockel L, Lohrke J, Pietsch H (2017) Quantification and assessment of the chemical form of residual gadolinium in the brain after repeated administration of gadolinium-based contrast agents comparative study in rats. Investig Radiol 52:396–404. https://doi.org/10.1097/Rli.0000000000000352 CrossRef

Frenzel T, Lengsfeld P, Schirmer H, Hutter J, Weinmann HJ (2008) Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Investig Radiol 43:817–828CrossRef

Greenberg SA (2010) Zinc transmetallation and gadolinium retention after MR imaging: case report. Radiology 257:670–673. https://doi.org/10.1148/radiol.10100560 CrossRefPubMed

Grobner T (2006) Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1745. https://doi.org/10.1093/ndt/gfl294 CrossRef

10.

Guerbet (2017) Advisory committee briefing document. Medical Imaging Drug Advisory Committee (MIDAC), 8 Sep 2017

11.

Hachmöller O, Aichler M, Schwamborn K, Lutz L, Werner M, Sperling M, Walch A, Karst U (2016) Element bioimaging of liver needle biopsy specimens from patients with Wilson’s disease by laser ablation-inductively coupled plasma-mass spectrometry. J Trace Elem Med Biol 35:97–102. https://doi.org/10.1016/j.jtemb.2016.02.001 CrossRefPubMed

12.

Hao DP, Ai T, Goerner F, Hu XM, Runge VM, Tweedle M (2012) MRI contrast agents: basic chemistry and safety. J Magn Reson Imaging 36:1060–1071. https://doi.org/10.1002/jmri.23725 CrossRefPubMed

13.

Jost G, Frenzel T, Lohrke J, Lenhard DC, Naganawa S, Pietsch H (2017) Penetration and distribution of gadolinium-based contrast agents into the cerebrospinal fluid in healthy rats: a potential pathway of entry into the brain tissue. Eur Radiol 27:2877–2885. https://doi.org/10.1007/s00330-016-4654-2 CrossRefPubMed

14.

Jost G, Lenhard DC, Sieber MA, Lohrke J, Frenzel T, Pietsch H (2016) Signal increase on unenhanced T1-weighted images in the rat brain after repeated, extended doses of gadolinium-based contrast agents comparison of linear and macrocyclic agents. Investig Radiol 51:83–89. https://doi.org/10.1097/Rli.0000000000000242 CrossRef

15.

Kanda T, Fukusato T, Matsuda M, Toyoda K, Oba H, Kotoku J, Haruyama T, Kitajima K, Furui S (2015) Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 276:228–232. https://doi.org/10.1148/radiol.2015142690 CrossRefPubMed

16.

Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D (2014) High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 270:834–841. https://doi.org/10.1148/radiol.13131669 CrossRefPubMed

17.

Kanda T, Osawa M, Oba H, Toyoda K, Kotoku J, Haruyama T, Takeshita K, Furui S (2015) High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology 275:803–809. https://doi.org/10.1148/radiol.14140364 CrossRefPubMed

18.

Künnemeyer J, Terborg L, Nowak S, Brauckmann C, Telgmann L, Albert A, Tokmak F, Krämer BK, Günsel A, Wiesmüller GA et al (2009) Quantification and excretion kinetics of a magnetic resonance imaging contrast agent by capillary electrophoresis-mass spectrometry. Electrophoresis 30:1766–1773. https://doi.org/10.1002/elps.2008-00831 CrossRefPubMed

19.

Künnemeyer J, Terborg L, Nowak S, Telgmann L, Tokmak F, Krämer BK, Günsel A, Wiesmüller GA, Waldeck J, Bremer C et al (2009) Analysis of the contrast agent magnevist and its transmetalation products in blood plasma by capillary electrophoresis/electrospray ionization time-of-flight mass spectrometry. Anal Chem 81:3600–3607. https://doi.org/10.1021/ac8027118 CrossRefPubMed

20.

Lauffer RB (1987) Paramagnetic metal-complexes as water proton relaxation agents for NMR imaging—theory and design. Chem Rev 87:901–927. https://doi.org/10.1021/Cr00081a003 CrossRef

21.

Lohrke J, Frisk AL, Frenzel T, Schöckel L, Rosenbruch M, Jost G, Lenhard DC, Sieber MA, Nischwitz V, Küppers A et al (2017) Histology and gadolinium distribution in the rodent brain after the administration of cumulative high doses of linear and macrocyclic gadolinium-based contrast agents. Investig Radiol 52:324–333. https://doi.org/10.1097/Rli.0000000000000344 CrossRef

22.

McDonald RJ, McDonald JS, Dai D, Schroeder D, Jentoft ME, Murray DL, Kadirvel R, Eckel LJ, Kallmes DF (2017) Comparison of gadolinium concentrations within multiple rat organs after intravenous administration of linear versus macrocyclic gadolinium chelates. Radiology. https://doi.org/10.1148/radiol.2017161594 PubMedCentralCrossRefPubMed

23.

McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Murray DL, Thielen KR, Williamson EE, Eckel LJ (2015) Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 275:772–782. https://doi.org/10.1148/radiol.15150025 CrossRefPubMed

24.

Murata N, Gonzalez-Cuyar LF, Murata K, Fligner C, Dills R, Hippe D, Maravilla KR (2016) Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue preliminary results from 9 patients with normal renal function. Investig Radiol. https://doi.org/10.1097/rli.0000000000000252 CrossRef

25.

Niehaus R, Sperling M, Karst U (2015) Study on aerosol characteristics and fractionation effects of organic standard materials for bioimaging by means of LA-ICP-MS. J Anal Atom Spectrom 30:2056–2065. https://doi.org/10.1039/c5ja00221d CrossRef

26.

Niehoff AC, Bauer OB, Kröger S, Fingerhut S, Schulz J, Meyer S, Sperling M, Jeibmann A, Schwerdtle T, Karst U (2015) Quantitative bioimaging to investigate the uptake of mercury species in Drosophila melanogaster. Anal Chem 87:10392–10396. https://doi.org/10.1021/acs.analchem.5b02500 CrossRefPubMed

27.

Oksendal AN, Hals PA (1993) Biodistribution and toxicity of MR imaging contrast-media. JMRI J Magn Reson Imaging 3:157–165. https://doi.org/10.1002/jmri.1880030128 CrossRefPubMed

28.

Puttagunta NR, Gibby WA, Smith GT (1996) Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. Investig Radiol 31:739–742. https://doi.org/10.1097/00004424-199612000-00001 CrossRef

29.

Radbruch A, Haase R, Kieslich PJ, Weberling LD, Kickingereder P, Wick W, Schlemmer HP, Bendszus M (2017) No signal intensity increase in the dentate nucleus on unenhanced T1-weighted MR images after more than 20 serial injections of macrocyclic gadolinium-based contrast agents. Radiology 282:699–707. https://doi.org/10.1148/radiol.2016162241 CrossRefPubMed

30.

Radbruch A, Roberts DR, Clement O, Rovira A, Quattrocchi CC (2017) Chelated or dechelated gadolinium deposition. Lancet Neurol 16:955CrossRefPubMed

31.

Radbruch A, Weberling LD, Kieslich PJ, Eidel O, Burth S, Kickingereder P, Heiland S, Wick W, Schlemmer HP, Bendszus M (2015) Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 275:783–791. https://doi.org/10.1148/radiol.2015150337 CrossRefPubMed

32.

Radbruch A, Weberling LD, Kieslich PJ, Hepp J, Kickingereder P, Wick W, Schlemmer HP, Bendszus M (2015) High-signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted images evaluation of the macrocyclic gadolinium-based contrast agent gadobutrol. Investig Radiol 50:805–810. https://doi.org/10.1097/Rli.0000000000000227 CrossRef

33.

Ramalho J, Castillo M, AlObaidy M, Nunes RH, Ramalho M, Dale BM, Semelka RC (2015) High signal intensity in globus pallidus and dentate nucleus on unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents. Radiology 276:836–844. https://doi.org/10.1148/radiol.2015150872 CrossRefPubMed

34.

Robert P, Lehericy S, Grand S, Violas X, Fretellier N, Idee JM, Ballet S, Corot C (2015) T1-weighted hypersignal in the deep cerebellar nuclei after repeated administrations of gadolinium-based contrast agents in healthy rats difference between linear and macrocyclic agents. Investig Radiol 50:473–480. https://doi.org/10.1097/Rli.0000000000000181 CrossRef

35.

Roberts DR, Welsh CA, LeBel DP 2nd, Davis WC (2017) Distribution map of gadolinium deposition within the cerebellum following GBCA administration. Neurology 88:1206–1208. https://doi.org/10.1212/WNL.0000000000003735 CrossRefPubMed

36.

Runge VM (2017) Critical questions regarding gadolinium deposition in the brain and body after injections of the gadolinium-based contrast agents, safety, and clinical recommendations in consideration of the EMA’s pharmacovigilance and risk assessment committee recommendation for suspension of the marketing authorizations for 4 linear agents. Investig Radiol 52:317–323. https://doi.org/10.1097/Rli.0000000000000374 CrossRef

37.

Runge VM, Stewart RG, Clanton JA, Jones MM, Lukehart CM, Partain CL, James AE (1983) Potential oral and intravenous paramagnetic NMR contrast agents. Radiology 147:789–791CrossRefPubMed

38.

Schindelin J, Arganda-Carreras I, Frise E et al (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9(7):676–682. https://doi.org/10.1038/nmeth.2019 CrossRefPubMed

39.

Telgmann L, Wehe CA, Künnemeyer J, Bülter AC, Sperling M, Karst U (2012) Speciation of Gd-based MRI contrast agents and potential products of transmetalation with iron ions or parenteral iron supplements. Anal Bioanal Chem 404:2133–2141. https://doi.org/10.1007/s00216-012-6404-x CrossRefPubMed

40.

Tweedle MF, Hagan JJ, Kumar K, Mantha S, Chang CA (1991) Reaction of gadolinium chelates with endogenously available ions. Magn Reson Imaging 9:409–415. https://doi.org/10.1016/0730-725x(91)90429-P CrossRefPubMed

41.

Vanwagoner M, Otoole M, Worah D, Leese PT, Quay SC (1991) A phase-I clinical-trial with gadodiamide injection, a nonionic magnetic-resonance-imaging enhancement agent. Investig Radiol 26:980–986CrossRef

42.

Vanwagoner M, Worah D (1993) Gadodiamide injection—1st human-experience with the nonionic magnetic-resonance-imaging enhancement agent. Investig Radiol 28:S44–S48

43.

Weinmann HJ, Laniado M, Mutzel W (1984) Pharmacokinetics of GdDTPA dimeglumine after intravenous-injection into healthy-volunteers. Physiol Chem Phys 16:167–172

44.

Yang XC, Sachs F (1989) Block of stretch-activated ion channels in xenopus oocytes by gadolinium and calcium-ions. Science 243:1068–1071. https://doi.org/10.1126/science.2466333 CrossRefPubMed

Titel: Gadolinium-based contrast agents induce gadolinium deposits in cerebral vessel walls, while the neuropil is not affected: an autopsy study
verfasst von: Stefanie Fingerhut
Michael Sperling
Markus Holling
Thomas Niederstadt
Thomas Allkemper
Alexander Radbruch
Walter Heindel
Werner Paulus
Astrid Jeibmann
Uwe Karst
Publikationsdatum: 10.05.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Acta Neuropathologica / Ausgabe 1/2018
Print ISSN: 0001-6322
Elektronische ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-018-1857-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

CADASIL brain vessels show a HTRA1 loss-of-function profile

A suggestion to introduce the diagnosis of “diffuse midline glioma of the pons, H3 K27 wildtype (WHO grade IV)”

Novel, improved grading system(s) for IDH-mutant astrocytic gliomas

Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers

Convective influx/glymphatic system: tracers injected into the CSF enter and leave the brain along separate periarterial basement membrane pathways